Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line

NCT02352337 is registered in ClinicalTrials.gov with Federation Francophone de Cancerologie Digestive as lead sponsor.

NCT NCT02352337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02352337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Lead sponsor
Federation Francophone de Cancerologie Digestive
Phase
Phase 2
Overall status
Completed
Start date
January 12, 2015
Completion date
August 31, 2021
Enrollment
276 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer